During EC therapy, ≥grade 3 hematological toxicities included neutropenia (61%), leukopenia (37%), FN (6.1%), anemia (2%), and an ASL/ALT increase (2%), while ≥grade 3 nonhematological toxicities included nausea (2%), appetite loss (2%), phlebitis (2%), and alopecia (2%). This evidence concerns the gene GPT and anemia.